These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7097493)

  • 1. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
    Simons KJ; Frith EM; Simons FE
    J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bio-availability of theophylline whole and halved sustained-release tablets.
    Müller FO; Hundt HK; Luus HG; van Dyk M; Groenewoud G; van der Meer MJ; Steinijans VW
    S Afr Med J; 1987 Aug; 72(3):175-8. PubMed ID: 3299763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet.
    Leeds NH; Gal P; Purohit AA; Walter JB
    J Clin Pharmacol; 1982 Apr; 22(4):196-200. PubMed ID: 7096605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products.
    Shargel L; Stevens JA; Fuchs JE; Yu AB
    J Pharm Sci; 1981 Jun; 70(6):599-602. PubMed ID: 7252799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.
    Shah VP; Yamamoto LA; Schuirman D; Elkins J; Skelly JP
    Pharm Res; 1987 Oct; 4(5):416-9. PubMed ID: 3508552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability and release pattern of whole and halved sustained-release theophylline tablets.
    Leeds NH; Gal P; Purohit AA; Walter JB
    Clin Pharm; 1982; 1(2):163-4. PubMed ID: 7185516
    [No Abstract]   [Full Text] [Related]  

  • 8. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
    Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
    Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of Theodel, a new theophylline tablet, in humans.
    Rovei V; Strolin Benedetti M; Donath A; Grenot C; Chanoine F
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):425-30. PubMed ID: 6629546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of whole and half Theo-Dur tablets.
    Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():62-6. PubMed ID: 6934089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet.
    Lagas M; Jonkman JH
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):424-6. PubMed ID: 4044074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.
    Jonkman JH; van der Boon WJ; Balant LP; Schoenmaker R; Holtkamp A
    Eur J Clin Pharmacol; 1984; 26(2):215-22. PubMed ID: 6723760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
    Bach JE; Kukanich B; Papich MG; McKiernan BC
    J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
    Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
    Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB; Schwartz RH; Brooks JG
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.